TRIAL DETAIL
Ph II Study of Perifosine Plus Gleevec for Patients With GIST
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Ph II Study of Perifosine Plus Gleevec for Patients With GIST |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumor |
|||
Status: |
Completed |
|||
Phase: |
2 |
Start Date 08/01/2006 |
Age of Trial (yrs) 17.7 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor + AKT inhibitor |
|||
Strategy: |
Block KIT + Block KIT Signal Path |
|||
Trial Type: |
Specifically GIST and only GIST |
|||
Other Protocol IDs: |
Perifosine 210 |
|||
Sponsor: |
Keryx / AOI Pharmaceuticals, Inc.
MD Anderson |
|||
Patient Contact: |
Online Collaborative Oncology Group |
|||
Contact email: |
ocogtrials@ocog.net |
|||
Contact Phone: |
415-946-2410 |
|||
Randomized: |
Randomized |
|||
IV or Oral: |
Oral |
|||
Trial Notes: |
Note: When contacting please refer to this study by ClinicalTrials.gov identifier NCT00455559. Note: OCOG is the single point of contact for all Perifosine trial sites. |
|||
Trial Links |
Trial Results |
Drug Information |
| Keryx drug page about perifosine |
| Ocular side effects associated with imatinib mesylate and perifosine for gastrointestinal stromal tumor |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
1505 Holcombe Blvd. |
Houston |
TX |
77030 |
USA |
|
1700 Luther Ln |
Park Ridge |
IL |
60068 |
USA |
|
2003 Lincoln Way |
Coeur d'Alene |
ID |
83814 |
USA |
|
Sayre |
PA |
18840 |
USA |
||
Grand Rapids |
MI |
49546 |
USA |